This Article Full Text Full Text (PDF) Supplementary Data, Hollestelle, et al. Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hollestelle, A. Articles by Schutte, M. Search for Related Content PubMed PubMed Citation Articles by Hollestelle, A. Articles by Schutte, M.

---

Signaling and Regulation

Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines

Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, the Netherlands

Requests for reprints: Mieke Schutte, Department of Medical Oncology, Josephine Nefkens Institute Be414, Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands. Phone: 31-10-4638-039; Fax: 31-10-4088-377. E-mail: a.schutte{at}erasmusmc.nl

Constitutive activation of the phosphatidylinositol-3-OH kinase (PI3K) and RAS signaling pathways are important events in tumor formation. This is illustrated by the frequent genetic alteration of several key players from these pathways in a wide variety of human cancers. Here, we report a detailed sequence analysis of the PTEN, PIK3CA, KRAS, HRAS, NRAS, and BRAF genes in a collection of 40 human breast cancer cell lines. We identified a surprisingly large proportion of cell lines with mutations in the PI3K or RAS pathways (54% and 25%, respectively), with mutants for each of the six genes. The PIK3CA, KRAS, and BRAF mutation spectra of the breast cancer cell lines were similar to those of colorectal cancers. Unlike in colorectal cancers, however, mutational activation of the PI3K pathway was mutually exclusive with mutational activation of the RAS pathway in all but 1 of 30 mutant breast cancer cell lines (P = 0.001). These results suggest that there is a fine distinction between the signaling activators and downstream effectors of the oncogenic PI3K and RAS pathways in breast epithelium and those in other tissues. (Mol Cancer Res 2007;5(2):195–201)

This article has been cited by other articles:

				A. Swarbrick, E. Roy, T. Allen, and J. M. Bishop Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response PNAS, April 8, 2008; 105(14): 5402 - 5407. [Abstract] [Full Text] [PDF]

				N. T. Woods, H. Yamaguchi, F. Y. Lee, K. N. Bhalla, and H.-G. Wang Anoikis, Initiated by Mcl-1 Degradation and Bim Induction, Is Deregulated during Oncogenesis Cancer Res., November 15, 2007; 67(22): 10744 - 10752. [Abstract] [Full Text] [PDF]

				H. Konishi, B. Karakas, A. M. Abukhdeir, J. Lauring, J. P. Gustin, J. P. Garay, Y. Konishi, E. Gallmeier, K. E. Bachman, and B. H. Park Knock-in of Mutant K-ras in Nontumorigenic Human Epithelial Cells as a New Model for Studying K-ras Mediated Transformation Cancer Res., September 15, 2007; 67(18): 8460 - 8467. [Abstract] [Full Text] [PDF]